| Literature DB >> 20606604 |
Martin J Hoogduijn1, Felix C Popp, Anja Grohnert, Meindert J Crop, Marieke van Rhijn, Ajda T Rowshani, Elke Eggenhofer, Philipp Renner, Marlies E Reinders, Ton J Rabelink, Luc J W van der Laan, Frank J M F Dor, Jan N M Ijzermans, Paul G Genever, Claudia Lange, Antoine Durrbach, Jaco H Houtgraaf, Bruno Christ, Martina Seifert, Murat Shagidulin, Vincent Donckier, Robert Deans, Olle Ringden, Norberto Perico, Giuseppe Remuzzi, Amelia Bartholomew, Hans J Schlitt, Willem Weimar, Carla C Baan, Marc H Dahlke.
Abstract
There is evolving interest in the use of mesenchymal stem cells (MSC) in solid organ transplantation. Pre-clinical transplantation models show efficacy of MSC in prolonging graft survival and a number of clinical studies are planned or underway. At a recent meeting of the MISOT consortium (MSC In Solid Organ Transplantation) the advances of these studies were evaluated and mechanisms underlying the potential effects of MSC discussed. Continued discussion is required for definition of safety and eventually efficacy endpoints for MSC therapy in solid organ transplantation.Mesh：
Year: 2010 PMID： 20606604 DOI： 10.1097/TP.0b013e3181ea4240
Source DB: PubMed Journal: Transplantation ISSN： 0041-1337 Impact factor: 4.939